Directing cancer cells to self-destruct with pro-apoptotic receptor agonists (Q37319386)

19 August 2017

1 reference

title

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists (English)

1 reference

19 August 2017

0 references

Avi Ashkenazi

1 reference

19 August 2017

publication date

7 November 2008

1 reference

Nature Reviews Drug Discovery

19 August 2017

published in

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

1001-1012

1 reference

19 August 2017

cites work

Cancer statistics, 2008

1 reference

Making progress against cancer in Europe in 2008.

31 March 2020

1 reference

Current concepts in apoptosis: the physiological suicide program revisited.

31 March 2020

1 reference

Apoptosis: a review of programmed cell death

31 March 2020

1 reference

31 March 2020

Physiology of apoptosis

1 reference

Activation of caspase-8 in the Alzheimer's disease brain

31 March 2020

1 reference

Caspases in Huntington's disease

31 March 2020

1 reference

Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in vivo adult cardiac cells

31 March 2020

1 reference

Cloning and expression of rat caspase-6 and its localization in renal ischemia/reperfusion injury

31 March 2020

1 reference

Apoptosis and autoimmune disorders

31 March 2020

1 reference

Apoptosis in the development and treatment of cancer

31 March 2020

1 reference

Caspase family proteases and apoptosis

31 March 2020

1 reference

Caspases: pharmacological manipulation of cell death

31 March 2020

1 reference

Caspases: a decade of death research

31 March 2020

1 reference

A unified model for apical caspase activation

31 March 2020

1 reference

Apoptotic DNA fragmentation

31 March 2020

1 reference

The role of the Bcl-2 protein family in cancer

31 March 2020

1 reference

Pharmacological manipulation of Bcl-2 family members to control cell death

31 March 2020

1 reference

The apoptosome: heart and soul of the cell death machine

31 March 2020

1 reference

The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet.

31 March 2020

1 reference

Death receptors: signaling and modulation

31 March 2020

1 reference

Apoptosis by death factor

31 March 2020

1 reference

The CD95(APO-1/Fas) DISC and beyond

31 March 2020

1 reference

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

31 March 2020

1 reference

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

31 March 2020

1 reference

Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis

31 March 2020

1 reference

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

31 March 2020

1 reference

Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling

31 March 2020

1 reference

Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death.

31 March 2020

1 reference

The role of receptor internalization in CD95 signaling

31 March 2020

1 reference

Death-receptor activation halts clathrin-dependent endocytosis

31 March 2020

1 reference

Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis

31 March 2020

1 reference

NF-kappaB at the crossroads of life and death

31 March 2020

1 reference

Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes

31 March 2020

1 reference

Tumor necrosis factor: an apoptosis JuNKie?

31 March 2020

1 reference

Diagnosing and exploiting cancer's addiction to blocks in apoptosis

31 March 2020

1 reference

c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis

31 March 2020

1 reference

Death and anti-death: tumour resistance to apoptosis

31 March 2020

1 reference

p53, the cellular gatekeeper for growth and division

31 March 2020

1 reference

Targeting apoptosis pathways in cancer therapy

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Alterations in the apoptotic machinery and their potential role in anticancer drug resistance

31 March 2020

1 reference

Intrinsic tumour suppression

31 March 2020

1 reference

Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding

31 March 2020

1 reference

Apoptosis: a relevant tool for anticancer therapy

31 March 2020

1 reference

Cytogenetic evolution of follicular lymphoma

31 March 2020

1 reference

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

31 March 2020

1 reference

Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.

31 March 2020

1 reference

RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis

31 March 2020

1 reference

Apoptosis, cancer and the p53 tumour suppressor gene

31 March 2020

1 reference

Mcl-1: a gateway to TRAIL sensitization.

31 March 2020

1 reference

Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme

31 March 2020

1 reference

LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization

31 March 2020

1 reference

Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis

31 March 2020

1 reference

A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death

31 March 2020

1 reference

Synergistic inhibition of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human pancreatic β cells by Bcl-2 and X-linked inhibitor of apoptosis

31 March 2020

1 reference

Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor

31 March 2020

1 reference

The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma

31 March 2020

1 reference

Lethal effect of the anti-Fas antibody in mice

31 March 2020

1 reference

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

31 March 2020

1 reference

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

31 March 2020

1 reference

Targeting death receptors in cancer with Apo2L/TRAIL.

31 March 2020

1 reference

Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies

31 March 2020

1 reference

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

31 March 2020

1 reference

Identification and characterization of a new member of the TNF family that induces apoptosis

31 March 2020

1 reference

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

31 March 2020

1 reference

TRAIL and apoptosis induction by TNF-family death receptors.

31 March 2020

1 reference

The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells

31 March 2020

1 reference

Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1.

31 March 2020

1 reference

CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

31 March 2020

1 reference

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

31 March 2020

1 reference

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

31 March 2020

1 reference

DR5 receptor mediates anoikis in human colorectal carcinoma cell lines.

31 March 2020

1 reference

TRAIL-R as a negative regulator of innate immune cell responses.

31 March 2020

1 reference

Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil

31 March 2020

1 reference

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

31 March 2020

1 reference

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

31 March 2020

1 reference

KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene

31 March 2020

1 reference

Safety and antitumor activity of recombinant soluble Apo2 ligand

31 March 2020

1 reference

Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

31 March 2020

1 reference

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

31 March 2020

1 reference

A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death

31 March 2020

1 reference

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

31 March 2020

1 reference

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

31 March 2020

1 reference

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

31 March 2020

1 reference

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

31 March 2020

1 reference

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

31 March 2020

1 reference

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

31 March 2020

1 reference

Regulation of apoptosis in the immune system

31 March 2020

1 reference

Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL

31 March 2020

1 reference

To kill a tumor cell: the potential of proapoptotic receptor agonists

31 March 2020

1 reference

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

31 March 2020

1 reference

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

31 March 2020

1 reference

Who should be sent for genetic testing in hereditary colorectal cancer syndromes?

31 March 2020

1 reference

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

31 March 2020

1 reference

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

31 March 2020

1 reference

TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice

31 March 2020

1 reference

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

31 March 2020

1 reference

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

31 March 2020

1 reference

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

31 March 2020

1 reference

Purification and characterization of recombinant sTRAIL expressed in Escherichia coli

31 March 2020

1 reference

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

31 March 2020

1 reference

Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts

31 March 2020

1 reference

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

31 March 2020

1 reference

The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice

31 March 2020

1 reference

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

31 March 2020

1 reference

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

31 March 2020

1 reference

Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts

31 March 2020

1 reference

Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inh

31 March 2020

1 reference

Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

31 March 2020

1 reference

Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.

31 March 2020

1 reference

Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

31 March 2020

1 reference

Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs

31 March 2020

1 reference

Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

31 March 2020

1 reference

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells

31 March 2020

1 reference

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

31 March 2020

1 reference

The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation

31 March 2020

1 reference

Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms

31 March 2020

1 reference

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

31 March 2020

1 reference

The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis

31 March 2020

1 reference

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

31 March 2020

1 reference

Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation

31 March 2020

1 reference

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

31 March 2020

1 reference

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling

31 March 2020

1 reference

Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.

31 March 2020

1 reference

Apo2L/TRAIL and its death and decoy receptors

31 March 2020

1 reference

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.

31 March 2020

1 reference

Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients

31 March 2020

1 reference

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

31 March 2020

1 reference

Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

31 March 2020

1 reference

Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation.

31 March 2020

1 reference

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype

31 March 2020

1 reference

Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide

31 March 2020

1 reference

Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

31 March 2020

1 reference

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies

31 March 2020

1 reference

The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis.

31 March 2020

1 reference

Live or let die: the cell's response to p53

31 March 2020

1 reference

Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery

31 March 2020

1 reference

Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis.

31 March 2020

1 reference

Regulation of lymphocyte proliferation and death by FLIP.

31 March 2020

1 reference

Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling

31 March 2020

1 reference

Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane

31 March 2020

1 reference

Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2637

1 reference

19 August 2017

1 reference